PHCentral RSS - rss FIRE feed Sat, 25 Oct 2014 00:10:35 GMT ‘Dead heart’ transplant breakthrough at St Vincent’s Hospital October 24, 2014 New PAH Research Highlights Effect of Disease on Muscles, Importance of Exercise October 24, 2014 Plant grown treatment for pulmonary hypertension October 24, 2014
In studies, Pharmaceutical International reports, the drug has been administered to rats. These studies found that the pulmonary hypertension levels in the rats dropped by around 20 percent. After two weeks of administration, the pressure levels inside the rats decreased by a further 12 percent. The rat based-trials not only produced pulmonary hypertension pressure drops of more than 30 percent, the drug further helped to improve heart function. The studies were conducted by the American Heart Association and the National Heart, Lung and Blood Institute.]]>
Actelion intends to file for selexipag's approval for PAH in the U.S. and the EU soon October 23, 2014 According to Actelion's 3Q Earnings-Report..]]> Pluristem Advances its Second Major Cell Therapy Product Line from Development to Large-Scale Manufacturing October 22, 2014 FDA Approves Ofev and Esbriet for Idiopathic Pulmonary Fibrosis October 21, 2014
Individuals with IPF have progressively scarred lungs over time and experience shortness of breath, cough, and difficulty participating in normal daily activities.

Prior to these approvals, treatments for IPF included oxygen therapy, pulmonary rehabilitation, and lung transplantation.

Nintedanib  and pirfenidone  were granted approval through a triple-path process: fast track, orphan product, and breakthrough designations. The approvals today come ahead of pirfenidone's and nintedanib's expected approval dates of November 23, 2014, and January 2, 2015, respectively...

PH Patient Hemodynamics Unaffected By Noninvasive Ventilation October 21, 2014 Until this study,”Hemodynamic Effects of Noninvasive Ventilation in Patients with Venocapillary Pulmonary Hypertension,” published in SciELO, was conducted, little was known about the hemodynamic effects of CPAP on patients with pulmonary hypertension without left ventricular dysfunction. The team studied 38 pulmonary hypertension patients..]]> Pulmonary arterial hypertension-related myopathy: An overview of current data and future perspectives October 20, 2014 Several cellular abnormalities are present in skeletal muscle of PAH patients.
These abnormalities finally culminate in muscle atrophy and reduced contractility.
Exercise training improves muscle function and clinical outcomes..

Pulmonary Hypertension & Pulmonary Arterial Hypertension: Categories, Risk Factors And Treatments Profiled October 19, 2014 A Crossover Randomised Controlled Trial of Oral Mandibular Advancement Devices for Obstructive Sleep Apnoea-Hypopnoea (TOMADO) October 19, 2014 Pulmonary Arterial Hypertension: A Better Understanding of the Three New Drug Therapies October 18, 2014 New Insights Into Hypoxia-induced Pulmonary Hypertension Reveal Key Signaling Pathways October 18, 2014 Journal of Cellular Physiology reports that both mTORC1 and Notch3 signaling pathways are associated with Hypoxia-Induced Pulmonary Hypertension.]]> Researchers Determine eRAP As Viable PAH Prognosticator October 17, 2014 HRQoL goals may improve outcome in PAH October 17, 2014 Vascular receptor autoantibodies implicated in SSc-PAH MedWire News October 17, 2014 PAH Combination Therapy Lowers Hospitalization Rate & Worsening PAH in New study October 17, 2014 Swedish-Built Machine Makes Lung Transplants More Available October 16, 2014 Sarcoidosis-associated pulmonary hypertension and lung transplantation for sarcoidosis October 15, 2014
Pulmonary hypertension (PH) is a significant complication of sarcoidosis, occurring in approximately 6 to > 20% of cases, and markedly increases mortality among these patients. The clinician should exercise a high index of suspicion for sarcoidosis-associated PH (SAPH) given the nonspecific symptomatology and the limitations of echocardiography in this patient population. The pathophysiology of PH in sarcoidosis is complex and multifactorial. Importantly, there are inherent differences in the pathogenesis of SAPH compared with idiopathic pulmonary arterial hypertension, making the optimal management of SAPH controversial. In this article, we review the epidemiology, diagnosis, prognosis, and treatment considerations for SAPH. Lung transplantation (LT) is a viable therapeutic option for sarcoid patients with severe pulmonary fibrocystic sarcoidosis or SAPH refractory to medical therapy. We discuss the role for LT in patients with sarcoidosis, review the global experience with LT in this population, and discuss indications and contraindications to LT.]]>
Emergy Department Diagnosis of PH October 14, 2014 Quebec is First Canadian Province to Publicly Fund Novel Oral PAH Treatment October 14, 2014 What Doctors Can Tell About Your Health Just By Looking At Your Feet October 13, 2014 ]]> 5 Victorian diseases back to haunt us October 13, 2014 But, with reports of an alarming rise in everything from rickets to gout, it appears certain diseases have not.
While we might be loving all things retro at the moment, filling our homes with mid-century sofas and dressing in questionable fashions of the 80s, we look at one vintage trend we don’t want be following…]]>
New Insights Into Monocrotaline Induced Pulmonary Hypertension October 13, 2014 Xolair Asthma Drug Associated With Higher Rate Of Heart Attacks, Pulmonary Hypertension, Blood Clots Causing PEs And/Or DVTs, And Brain Blood Vessel Problems October 12, 2014 Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? October 12, 2014 PAH Treatments Could Be Developed From New Insights Into a Molecule in the Glycolytic Pathway October 11, 2014 Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema October 11, 2014 Chronic Thromboembolic Pulmonary Hypertension Disease Progression Mechanisms Uncovered October 10, 2014 Pulmonary Hypertension Can Complicate Treatment in the ICU October 10, 2014 An Implanted Sensor Is Helping Heart Patients October 9, 2014 Confused Drug Names October 8, 2014 LETARIS is a formerly marketed Dutch brand name for letrozole, which is indicated for the treatment of local or metastatic breast cancer that is hormone receptor–positive or breast cancer with unknown receptor status in postmenopausal women. Letrozole is known by the brand name FEMARA in the United States. LETAIRIS (note the “I” after the “A”) is ambrisentan, a drug approved by the FDA for primary pulmonary hypertension.]]> Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness October 8, 2014 The 2014-2015 Flu Season: Vaccine Recommendations October 7, 2014 Targeted treatments may improve idiopathic PAH survival October 5, 2014 Data for Promedior’s Idiopathic Pulmonary Fibrosis Drug PRM-151 Released October 5, 2014 Producing Pulmonary Drugs in Plant Cells May Allow for Cheaper Treatments October 4, 2014
In murine studies, angiotensin-converting enzyme 2 (ACE2) and its enzymatic product, angiotensin-(1-7) bioencapsulated in plant cells were effective against pulmonary hypertension.]]>
Pulmonary Arterial Hypertension Patients With Congenital Heart Disease Experience Poor Quality of Life Scores October 4, 2014 The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension October 3, 2014 [..]
The use of antidepressants was associated with a significantly increased risk of developing IPAH. However, the consistency of this risk across all antidepressants and absence of a dose-response relationship suggests a non-causal association.]]>
Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients October 3, 2014 [..]
This study is the first to show that IP-10 secretion is associated with poor pulmonary haemodynamics and physical capacity in CTEPH and might be involved in the pathological mechanism of PEA tissue formation.]]>
APT Therapeutics’ Apyrase-Based Investigational Drug Minimizes Damage from Heart Attack without Increasing Hemorrhage October 3, 2014 [..]
APT Therapeutics™ is developing optimized human apyrases as safe and effective therapy for acute myocardial infarction, stroke and pulmonary arterial hypertension.]]>
Bayer closes acquisition of Consumer Care Business of Merck & Co. Inc October 2, 2014 [..]
The strategic pharma collaboration between Bayer and Merck & Co., Inc. in the field of soluble guanylate cyclase (sGC) modulators also comes into effect simultaneously. Bayer plans to strengthen its development options in the cardiology business with the global co-development and co-commercialization agreement, which has already been approved by the relevant antitrust authorities. Merck & Co., Inc. will make payments of up to USD 2.1 billion to Bayer. These include an up-front payment of USD 1 billion, which is to be paid shortly after completion as well as revenue-based milestone payments of up to USD 1.1 billion for future combined sales of certain jointly developed substances, including the pulmonary hypertension treatment Adempas? (riociguat)...]]>
Correcting Cardiac Arrhythmias in PAH Patients Can Improve Mortality Risk October 1, 2014 Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis October 1, 2014 The study involved 1695 patients at a single cardiac care centre who underwent Doppler echocardiography no more than 5 days before or after right heart catheterisation. 
Researcher Sebastian Greiner (University of Heidelberg, Germany) and team say that their study is considerably larger than most previous analyses of noninvasive systolic pulmonary artery pressure (sPAP) measurement.
“Although recommended in many guidelines and used routinely, noninvasive quantification of sPAP has never been tested sufficiently in unselected large patient populations undergoing routine echocardiography examination”, they write in the Journal of the American Heart Association...]]>
Acute Hemodynamic Response of Infused Fasudil in Patients with Pulmonary Arterial Hypertension: A Randomized, Controlled, Crossover Study September 30, 2014 Iloprost reverses established fibrosis in experimental right ventricular failure. September 30, 2014 Hydrogen (H2) als PAH-treatment? September 29, 2014 New Targets For Pulmonary Arterial Hypertension Treatments Identified By Researchers September 28, 2014 American Journal of Respiratory and Critical Care Medicine, entitled, “The Sphingosine Kinase 1 / Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension” reports the discovery of two novel therapeutic targets to treat pulmonary arterial hypertension.]]> Lungs Affected by Idiopathic Pulmonary Fibrosis May Benefit From Inflammation September 28, 2014 Trial Data Supporting Safety and Efficacy of FibroGen FG-3019 Idiopathic Pulmonary Fibrosis Drug Presented At ICLAF Colloquium September 28, 2014 Patient-derived stem cells shed light on pulmonary hypertension September 27, 2014 Right Ventricular Geometry and Function in Pulmonary Hypertension: Non-Invasive Evaluation September 27, 2014 Researchers Uncover New Insights Into Vascular Receptor Autoantibodies in PAH Associated with SSc September 27, 2014 American Journal of Respiratory and Critical Care Medicine by first author on the study Dr. Mike O. Becker from the group of Dr. Gabriela Riemekasten, reveals that antibodies against endothelin receptor type A (ETAR) and angiotensin receptor type-1 (AT1R) are involved in Systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) pathogenesis.]]> Ontarians Celebrate Overdue Provincial Access to Only IPF Treatment September 26, 2014 Sarcoidosis-Associated Pulmonary Hypertension Highlighted By Recent Study September 26, 2014 Seminars in Respiratory and Critical Care Medicine state that approximately 6-20% of sarcoidosis patients will develop pulmonary hypertension and see an increased risk of mortality.]]> Surgery corrects pulmonary problem September 25, 2014